Community-Engaged Covid-19 Interventions to Protect and Monitor Children
Project Number3R01ES028615-07S1
Former Number7R01ES028615-06
Contact PI/Project LeaderAL-HENDY, AYMAN Other PIs
Awardee OrganizationUNIVERSITY OF CHICAGO
Description
Abstract Text
PROJECT SUMMARY/ABSTRACT
This Administrative Supplement will focus on low-income Black and Latinx children and their families in the
Chicagoland metro area. Three reasons drive the need for this additional support. First, the newer COVID-19
variant strains have shown increased susceptibility for children. Second, COVID-19 vaccinations will soon be
approved for children under the age of 16, making them the next target for vaccination efforts. Third, schools will
be in person starting the fall of 2021, requiring frequent COVID-19 testing for children and their families. Our team
has partnered with MobileCare Chicago and the Chicagoland COVID Collaborative to address these issues.
MobileCare Chicago is a non-profit organization that provides clinical asthma and dental care using mobile medical
clinics (vans) that rotate among schools in a predominantly low-income, minority populations on the south and west
sides of Chicago. MobileCare Chicago has recently begun partnering with local health centers to leverage their
mobile community facilities to distribute COVID-19 vaccination to adults. The Chicagoland COVID Collaborative is
one of 21 National Institutes of Health (NIH) Community Engagement Research Alliance Against COVID-19
Disparities (CEAL) teams. Although led by the University of Illinois Chicago (UIC), the Chicagoland COVID
Collaborative includes six other co-principal investigators and their institutions. This partnership of academic and
community health disparities experts is working together to improve COVID-19 vaccination and engagement in
quality therapeutic care and trials for low-income Black and Latinx communities in the Chicago area. Some of the
lessons learned to date from earlier CEAL teams and the experiences of the Chicagoland COVID Collaborative
are the importance of (1) locating COVID-19 vaccination services in community locations, and (2) using community
health workers and other trusted messengers to spend time with individuals discussing their questions and
concerns around vaccination, and providing accurate information and problem-solving support. Our proposed work
with this supplement will co-locate COVID-19 testing with vaccination efforts directly at schools in low-income Black
and Latinx communities in Chicago using the MobileCare Chicago network and clinical vans. Children, their
families, community members, and school staff will all be offered COVID-19 testing and vaccination at their local
schools. They will also be offered counseling and information on COVID-19 testing and vaccination from trusted
staff at MobileCare Chicago. This proposed model leverages the lessons learned and infrastructure from the CEAL
and RADx-UP programs to date to enhance both COVID-19 testing and vaccination.
Public Health Relevance Statement
PROJECT NARRATIVE
This project will employ sentinel and community-based epidemiological surveillance and participatory research
methods to evaluate whether a person-centered, rapid COVID-19 testing and vaccination intervention coupled
with a novel mHealth COVID-19 Literacy and Outreach Suite of apps and videos, will serve to increase the
acceptance, access, reach, uptake, and impact of COVID-19 testing for children at the Chicago public school
and associated catchment areas. Children, their families, community members, and school staff will also be
offered COVID-19 testing at their local schools. We will use community health workers and MobileCare Chicago
trusted staff to spend time with individuals discussing their questions and concerns around testing and
vaccination, and providing accurate information and problem-solving support.
National Institute of Environmental Health Sciences
CFDA Code
113
DUNS Number
005421136
UEI
ZUE9HKT2CLC9
Project Start Date
11-November-2020
Project End Date
31-July-2023
Budget Start Date
01-September-2021
Budget End Date
31-July-2023
Project Funding Information for 2021
Total Funding
$300,000
Direct Costs
$297,064
Indirect Costs
$2,936
Year
Funding IC
FY Total Cost by IC
2021
NIH Office of the Director
$300,000
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 3R01ES028615-07S1
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 3R01ES028615-07S1
Patents
No Patents information available for 3R01ES028615-07S1
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 3R01ES028615-07S1
Clinical Studies
No Clinical Studies information available for 3R01ES028615-07S1
News and More
Related News Releases
No news release information available for 3R01ES028615-07S1
History
No Historical information available for 3R01ES028615-07S1
Similar Projects
No Similar Projects information available for 3R01ES028615-07S1